Overview

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib